Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease

[1]  A. Lang,et al.  Impulse control disorders in parkinson disease: A multicenter case–control study , 2011, Annals of neurology.

[2]  J. Matsumoto,et al.  Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies. , 2011, Parkinsonism & related disorders.

[3]  T. Münte,et al.  Pramipexole modulates the neural network of reward anticipation , 2011, Human brain mapping.

[4]  Marios Politis,et al.  Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. , 2011, Brain : a journal of neurology.

[5]  Z. Xi,et al.  PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats , 2011, Journal of psychopharmacology.

[6]  G. Belmonte,et al.  Parkinson's Disease and pathological gambling: Results from a functional MRI study , 2010, Movement disorders : official journal of the Movement Disorder Society.

[7]  B. Averbeck,et al.  Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[8]  John D. Beaver,et al.  Imaging Dopamine D3 Receptors in the Human Brain with Positron Emission Tomography, [11C]PHNO, and a Selective D3 Receptor Antagonist , 2010, Biological Psychiatry.

[9]  A. Lang,et al.  Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. , 2010, Archives of neurology.

[10]  A. Lawrence,et al.  Impulsive‐compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy , 2010, Movement disorders : official journal of the Movement Disorder Society.

[11]  Sylvain Houle,et al.  Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. , 2010, The international journal of neuropsychopharmacology.

[12]  H. Cohen,et al.  Compulsive habits in restless legs syndrome patients under dopaminergic treatment , 2010, Journal of the Neurological Sciences.

[13]  B. Le Foll,et al.  The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking. , 2010, The international journal of neuropsychopharmacology.

[14]  M. Hallett,et al.  Mechanisms Underlying Dopamine-Mediated Reward Bias in Compulsive Behaviors , 2010, Neuron.

[15]  S. Houle,et al.  Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. , 2009, Brain : a journal of neurology.

[16]  Stevens,et al.  Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. , 2009, Mayo Clinic proceedings.

[17]  M. Stacy,et al.  Impulse Control Disorders Arising in 3 Patients Treated With Rotigotine , 2009, Clinical neuropharmacology.

[18]  M. Millan,et al.  The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drug-seeking behavior in rats , 2009, Neuropharmacology.

[19]  H. Falhammar,et al.  Pathological gambling and hypersexuality in cabergoline‐treated prolactinoma , 2009, The Medical journal of Australia.

[20]  P. O'Suilleabhain,et al.  Risk factors for pathologic gambling and other compulsions among Parkinson’s disease patients taking dopamine agonists , 2007, Journal of Clinical Neuroscience.

[21]  K. Josephs,et al.  Unusual compulsive behaviors primarily related to dopamine agonist therapy in Parkinson's disease and multiple system atrophy. , 2007, Parkinsonism & related disorders.

[22]  O. Suchowersky,et al.  Pathological gambling associated with dopamine agonist use in restless legs syndrome. , 2007, Parkinsonism & related disorders.

[23]  M. Davie.  Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. , 2007, The Journal of neuropsychiatry and clinical neurosciences.

[24]  Andrew J Lees,et al.  Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series , 2007, Movement disorders : official journal of the Movement Disorder Society.

[25]  C. Adler,et al.  Gambling and Increased Sexual Desire With Dopaminergic Medications in Restless Legs Syndrome , 2007, Clinical neuropharmacology.

[26]  V. Voon,et al.  Medication-related impulse control and repetitive behaviors in Parkinson disease. , 2007, Archives of neurology.

[27]  A. Lang,et al.  Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. , 2007, Archives of neurology.

[28]  M. Silber,et al.  Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists , 2007, Neurology.

[29]  A. Lang,et al.  Prospective prevalence of pathologic gambling and medication association in Parkinson disease , 2006, Neurology.

[30]  C. Waters,et al.  Compulsive eating and weight gain related to dopamine agonist use , 2006, Movement disorders : official journal of the Movement Disorder Society.

[31]  Y. Geda,et al.  Pathological gambling caused by drugs used to treat Parkinson disease. , 2005, Archives of neurology.

[32]  J. Matsumoto,et al.  Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. , 2005, Parkinsonism & related disorders.

[33]  John Seibyl,et al.  Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. , 2004, Archives of neurology.

[34]  P. Riederer,et al.  Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum , 2003, Journal of Neural Transmission.

[35]  M. Stacy,et al.  Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease , 2003, Neurology.

[36]  Claude Nahmias,et al.  Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study , 2003, Annals of neurology.

[37]  John Seibyl,et al.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. , 2000, JAMA.

[38]  D. Brooks,et al.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. , 2000, The New England journal of medicine.

[39]  Bruno Giros,et al.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics , 1990, Nature.

[40]  M. Nirenberg,et al.  Dopamine agonist withdrawal syndrome in Parkinson disease. , 2010, Archives of neurology.

[41]  M. Silber,et al.  Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. , 2010, Sleep.

[42]  J. Joyce,et al.  Distribution of Dopamine D3 Receptor Expressing Neurons in the Human Forebrain: Comparison with D2 Receptor Expressing Neurons , 1999, Neuropsychopharmacology.